Navigation Links
San Diego's Original Biotech Company Celebrates 30th Anniversary With Reunion
Date:9/9/2008

Hybritech Alumni Launched the World's 3rd Largest Biotech Cluster By

Developing more than 175 Local Companies

SAN DIEGO, Sept. 9 /PRNewswire/ -- The Hybritech Reunion Committee today announced the 30th Anniversary Reunion for Hybritech employees will take place on Saturday, September 13th, 2008 at the headquarters of AMN Healthcare in San Diego.

In September 1978 Hybritech, San Diego's "Granddaddy" biotech company, began operations in temporary trailers located in the parking lot of the La Jolla Cancer Research Foundation (now the renowned Burnham Institute). The company quickly produced the world's first commercially manufactured monoclonal antibody product, and soon thereafter, a series of diagnostic kits for allergy, pregnancy, anemia and certain forms of cancer. The company was also instrumental in the earliest investigations of in vivo and therapeutic applications of monoclonal antibodies for the diagnosis and treatment of cancer.

By 1985, Hybritech had developed its "Prostate Specific Antigen (PSA)" product, the first monoclonal antibody test for prostate cancer. The blood test soon became the standard method for physicians to diagnose and monitor prostate cancer patients, the second biggest cancer killer among American men.

In 1986, the pharmaceutical company, Eli Lilly paid $450 million in cash and warrants to buy Hybritech -- at that point the largest M&A in San Diego history. The company's early success -- and the visibility it created among its founders and employees -- spurred other academic scientists and entrepreneurs to form dozens of additional life sciences companies in San Diego.

Hybritech's original founders and employees have gone on to found more than 175 of the several hundred life science companies now located in San Diego county -- and comprising the San Diego life sciences "technology cluster".

"This event is a milestone celebration of all the tremendous things that came from the genesis of this small company 30 years ago. Who would have foreseen how significant the impact of one company could be on our community's economy and its reputation as a leading area of biotech research and scientific development? I am very proud to have led this brilliant, dedicated and innovative group of individuals," said Ted Greene, chief executive of Hybritech until the Lilly acquisition.

"There are several hundred Hybritech alumni who continue to live and work here in San Diego who plan to attend the reunion. We also have former employees planning to attend who currently live across the United States and in Europe -- and who are returning to San Diego for the event. These Hybritech alumni rank among the earliest founders of San Diego's now vibrant biotech and life sciences 'technology cluster'. Many people, even former employees, are surprised to learn that the Hybritech success has become a point of study among academic and governmental investigators who want to understand how 'technology clusters' are successfully created and sustained," said Cole Owen, a member of the Hybritech Reunion Committee.

The Hybritech 30th Anniversary Reunion (for former Hybritech employees only) will be held at the AMN Healthcare facility in San Diego, on Saturday, September 13, 2008, beginning at 3 PM. The host for the Reunion is AMN's President and CEO, Susan Nowakowski, herself a Hybritech alumnus.

Further registration information is available online at http://www.Hybritech.org for former Hybritech employees and media.

The Hybritech Reunion is a non profit corporation dedicated to preserving the legacy of Hybritech.


'/>"/>
SOURCE Hybritech Reunion Committee
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
2. Three Expert Opinion Journals now Publishing Original Research
3. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
4. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
5. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
8. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
9. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
10. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
11. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):